Molecular mechanism of miRNA regulating PD-L1 expression

被引:0
|
作者
Zhao, Wenxin [1 ,2 ]
Li, Xiaolan [1 ,2 ]
Ren, Qunli [1 ,2 ]
Wang, Qian [1 ,2 ]
Liao, Chengcheng [2 ]
Ding, Tianhao [2 ]
Li, Ping [1 ]
Liu, Jianguo [2 ]
机构
[1] Zunyi Med Univ, Microbial Resources & Drug Dev Key Lab Guizhou Ter, Sch Stomatol, Zunyi 563000, Peoples R China
[2] Zunyi Med Univ, Sch Clin Med, Zunyi 563000, Peoples R China
来源
GENE REPORTS | 2023年 / 31卷
关键词
PD-L1; miRNA; Immune checkpoint; Molecular regulation; Tumor suppressor gene; BREAST-CANCER; TARGETS PD-L1;
D O I
10.1016/j.genrep.2023.101763
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
PD-L1 (programmed death-ligand 1) binding to PD-1 (programmed cell death protein 1) reduces the proliferation of PD-1-positive cells, inhibits their cytokine secretion, and induces apoptosis. miRNA (microRNA) as an important regulator of gene expression, affects the performance of gene function. Similarly, the expression of PDL1 is also regulated by miRNA. miRNAs usually negatively regulate gene expression, however, is there positive regulation? We reviewed the molecular mechanisms of the positive and negative regulation of PD-L1 expression by miRNAs. miRNAs mainly indirectly and positively regulate PD-L1 expression through the regulation of tumor suppressor genes PTEN (phosphatase and tensin homolog) and LATS2 (large tumor suppressor kinase 2), oncogene YAP1 (Yes1 associated transcriptional regulator), DNA damage response protein Ku80 (80-kilodalton subunit of the Ku heterodimer protein), etc., while negative regulation is mainly achieved by miRNAs directly binding to the 3 & PRIME;-UTR (3 & PRIME; untranslated region) of PD-L1 mRNA. And this negative regulation can also be reversed by the negative regulation of miRNAs by RNA-binding protein LIN28 (protein lin-28) or circRNAs (circular RNA) such as cire0000284 and circ-CPA4. The revealing of this mechanism provides more references and strategies for immune checkpoint therapy of tumors.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] PD1 and PD-L1 expression in glioblastoma
    Berghoff, Anna Sophie
    Kiesal, Barbara
    Widhalm, Georg
    Rajky, Orsolya
    Ricken, Garda
    Woehrer, Adelheid
    Dieckmann, Karin
    Filipits, Martin
    Zielinski, Christoph
    Marosi, Christine
    Hainfellner, Johannes A.
    Preusser, Matthias
    Wick, Wolfgang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Expression of the Extracellular Domain of Mouse PD-L1 and Production of Antibodies to PD-L1
    Goryunova, M. S.
    Ryazantsev, D. Yu.
    Petrova, E. E.
    Kostenko, V. V.
    Makarova, A. O.
    Kholodenko, R. V.
    Ryabukhina, E. V.
    Kalinovsky, D. V.
    Kotsareva, O. D.
    Svirshchevskaya, E. V.
    RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY, 2024, 50 (06) : 2644 - 2656
  • [33] Development of small-molecular-based radiotracers for PET imaging of PD-L1 expression and guiding the PD-L1 therapeutics
    Yang, Hongzhang
    Zeng, Xinying
    Liu, Jia
    Wen, Xuejun
    Liu, Huanhuan
    Liang, Yuanyuan
    Wang, Xueqi
    Fang, Jianyang
    Zhang, Qinglin
    Li, Jindian
    Zhang, Xianzhong
    Guo, Zhide
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (06) : 1582 - 1592
  • [34] Clinicopathological significance of PD-L1 expression in colorectal cancer: Impact of PD-L1 expression on pFOXO1 expression
    Pyo, Jung-Soo
    Ko, Soo Hee
    Ko, Young San
    Kim, Nae Yu
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (02)
  • [35] Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression
    Saito, Hiroaki
    Kono, Yusuke
    Murakami, Yuki
    Shishido, Yuji
    Kuroda, Hirohiko
    Matsunaga, Tomoyuki
    Fukumoto, Yoji
    Osaki, Tomohiro
    Ashida, Keigo
    Fujiwara, Yoshiyuki
    ANTICANCER RESEARCH, 2018, 38 (01) : 107 - 112
  • [36] Relevance of specific oncolytic adenovirus in regulating PD-L1 expression in prostate cancer
    Zhang, Di
    Jin, Tong-Tong
    Lu, Tian-Yi
    Zhou, Feng-Hai
    ASIAN JOURNAL OF SURGERY, 2023, 46 (05) : 2252 - 2253
  • [37] Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
    Hyun Tae Lee
    Ju Yeon Lee
    Heejin Lim
    Sang Hyung Lee
    Yu Jeong Moon
    Hyo Jeong Pyo
    Seong Eon Ryu
    Woori Shin
    Yong-Seok Heo
    Scientific Reports, 7
  • [38] Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
    Lee, Hyun Tae
    Lee, Ju Yeon
    Lim, Heejin
    Lee, Sang Hyung
    Moon, Yu Jeong
    Pyo, Hyo Jeong
    Ryu, Seong Eon
    Shin, Woori
    Heo, Yong-Seok
    SCIENTIFIC REPORTS, 2017, 7
  • [39] Identification and validation of a PD-L1 specific peptide for determination of PD-L1 expression in tumors
    Caldwell, Charles
    Johnson, Cory
    Hammer, Richard
    Kannan, Raghuraman
    CANCER RESEARCH, 2017, 77
  • [40] Comparison o PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma
    Yokoyama, Shintaro
    Miyoshi, Hiroaki
    JOURNAL OF THORACIC DISEASE, 2020, 12 (12) : 7553 - 7560